A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.
With a slight asynchronous but consistent progression, all of the mammary glands of female BALB/c mice transgenic for the transforming rat HER-2/neu oncogene progress to atypical hyperplasia and to invasive carcinoma. Previous studies have shown that chronic administration of interleukin (IL) 12 started at the 2nd week of age hampers this progression because of its ability to inhibit tumor angiogenesis and activate a nonspecific immune response. Here we show that a similar inhibition is achieved when 7-week-old mice with fully blown atypical hyperplasia receive a weekly injection of 100 ng IL-12 for 16 times. This lower-dose and later IL-12 administration induces high and sustained levels of serum IFN-gamma equivalent to those elicited by more frequent administrations. A lower-dose and less toxic treatment may thus be envisaged as a possible option in the management of preneoplastic mammary lesions.
Cifaldi
L
L
Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
Quaglino
E
E
Di Carlo
E
E
Musiani
P
P
Spadaro
M
M
Lollini
P L
PL
Wolf
S
S
Boggio
K
K
Forni
G
G
Cavallo
F
F
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics*; D006965:Hyperplasia / Q000473:pathology; D007371:Interferon-gamma / Q000096:biosynthesis; D018664:Interleukin-12 / Q000494:pharmacology*; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic
D018664:Interleukin-12; D007371:Interferon-gamma